VYVANSE

Revenues have reached $319 million this year.

“VYVANSE helps me to concentrate and I'm making friends and enjoying school.”
Macey Owens

VYVANSE is an innovative new pro-drug therapy for Attention Deficit Hyperactivity Disorder (ADHD), which only becomes active when it is metabolized in the body. This means it offers a steady benefit throughout the day. For more information on Shire products visit http://www.shire.com/shire/products/

Focus on the science - Specialty Pharma

Putting it into practice

We organize our business around our patients, and around the type and prevalence of the diseases we treat.